Research ArticleCancer

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

See allHide authors and affiliations

Science Translational Medicine  17 Jan 2018:
Vol. 10, Issue 424, eaan5488
DOI: 10.1126/scitranslmed.aan5488

Article Information

vol. 10 no. 424

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication May 2, 2017
  • Resubmitted October 4, 2017
  • Accepted for publication November 13, 2017

Author Information

  1. Yan Lan*,
  2. Dong Zhang,
  3. Chunxiao Xu,
  4. Kenneth W. Hance,
  5. Bo Marelli,
  6. Jin Qi,
  7. Huakui Yu,
  8. Guozhong Qin,
  9. Aroop Sircar,
  10. Vivian M. Hernández,
  11. Molly H. Jenkins,
  12. Rachel E. Fontana,
  13. Amit Deshpande,
  14. George Locke,
  15. Helen Sabzevari,
  16. Laszlo Radvanyi and
  17. Kin-Ming Lo*
  1. EMD Serono Research and Development Institute Inc., Billerica, MA 01821, USA.
  1. *Corresponding author. Email: yan.lan{at}emdserono.com (Y.L.); kinming.lo{at}emdserono.com (K.-M.L.)
  • Present address: GlaxoSmithKline, Collegeville, PA 19426, USA.

  • Present address: Intrexon Corporation, Germantown, MD 20876, USA.

Altmetric

Article usage

Article usage: January 2018 to May 2019

AbstractFullPdf
Jan 201873735171228
Feb 20181280155351
Mar 20181216189410
Apr 201876993241
May 20181292136312
Jun 2018935146207
Jul 201860299146
Aug 2018440202160
Sep 2018361137109
Oct 2018429165165
Nov 2018519163153
Dec 2018380110108
Jan 2019185270259
Feb 201961772774
Mar 201938452520
Apr 201919381400
May 201947244303

Navigate This Article